Rapport Therapeutics, Inc. (RAPP) Stock Statistics & Valuation Metrics

Rapport Therapeutics, Inc. has a market cap or net worth of $1.20B. The enterprise value is $1.55B.

Market Cap

$1.20B

Enterprise Value

$1.55B

Rapport Therapeutics, Inc. has 47,978,287 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

47,978,287

Owned by Insiders

25.07%

Owned by Institutions

38.95%

Rapport Therapeutics, Inc.’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -25.21%.

Return on Equity (ROE)

-0.23

Return on Assets (ROA)

-0.22

Return on Invested Capital (ROIC)

-25.21%

Return on Capital Employed (ROCE)

-0.25

Revenue Per Employee

0

Profits Per Employee

-1.33M

Employee Count

84

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Rapport Therapeutics, Inc. is -8.24. Rapport Therapeutics, Inc.’s PEG ratio is 0.38.

PE Ratio

-8.24

PS Ratio

60.09

PB Ratio

2.81

Price to FCF

-12.37

Price to Operating Cash Flow

-12.30

PEG Ratio

0.38

In the last 12 months, Rapport Therapeutics, Inc. had revenue of 0 and earned -111.48M in profits. Earnings per share was -2.86.

Revenue

0

Gross Profit

-1.02M

Operating Income

-125.10M

Pretax Income

-111.48M

Net Income

-111.48M

EBITDA

-124.08M

Earnings Per Share (EPS)

-2.86

In the last 12 months, operating cash flow was -96.68M and capital expenditures -467,000, giving a free cash flow of -97.15M billion.

Operating Cash Flow

-96.68M

Free Cash Flow

-97.15M

Free Cash Flow per Share

-2.05

Rapport Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-8.08%

Earnings Yield

-11.53%

Beta

1.69

52-Week Price Change

-6.81%

50-Day Moving Average

37.12

200-Day Moving Average

35.85

Relative Strength Index (RSI)

37.55

Average Volume (3m)

695.80K

Rapport Therapeutics, Inc. upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 05, 2026

Next Earnings Date

Nov 05, 2026

Ex-Dividend Date

―

Rapport Therapeutics, Inc. as a current ratio of 26.17, with Debt / Equity ratio of 2.37%

Current Ratio

26.17

Quick Ratio

26.17

Debt to Market Cap

0.01

Net Debt to EBITDA

0.33

Interest Coverage Ratio

0.00

In the past 12 months, Rapport Therapeutics, Inc. has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Rapport Therapeutics, Inc. EV to EBITDA ratio is -7.74, with an EV/FCF ratio of -11.82.

EV to Sales

57.42

EV to EBITDA

-7.74

EV to Free Cash Flow

-11.82

EV to Operating Cash Flow

-11.88

Rapport Therapeutics, Inc. has $436.08M in cash and marketable securities with $10.11M in debt, giving a net cash position of $425.97M billion.

Cash & Marketable Securities

$436.08M

Total Debt

$10.11M

Net Cash

$425.97M

Net Cash Per Share

$8.88

Tangible Book Value Per Share

$8.91

Gross margin is 100.00%, with operating margin of -767.58%, and net profit margin of -685.80%.

Gross Margin

100.00%

Operating Margin

-767.58%

Pretax Margin

-685.80%

Net Profit Margin

-685.80%

EBITDA Margin

-741.82%

EBIT Margin

-746.63%

The average price target for Rapport Therapeutics, Inc. is $69.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$69.40

Price Target Upside

177.05% Upside

Analyst Consensus

Strong Buy

Analyst Count

13

Revenue Growth Forecast

―

EPS Growth Forecast

-23.53%

Smart Score

10

AI Score

53